Company
Headquarters: Taipei, Taiwan
CEO: Dr. Yue-Teh Jang
TW$8.68 Billion
TWD as of Jan. 1, 2026
US$277.1 Million
| Company | Market Cap (USD) |
|---|---|
| Intuitive | $201.46 B |
| EssilorLuxottica SA | $144.43 B |
| Becton, Dickinson and Company | $55.63 B |
| HOYA Corp | $50.63 B |
| Alcon Inc. | $39.46 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Medeon Biodesign, Inc. develops and markets medical device solutions in Taiwan. It focuses on developing devices for minimally invasive surgeries, such as Duett, a vascular graft system; ClickClean, a solution to view throughout laparoscopic surgeries; AbClose to prevent port site herniation caused by improper closure; UroCross, an expander system; PUMA, a solution to treat orthopedic extremity injuries; and Cross-Seal, a large-bore closure device. The company was founded in 2012 and is headquartered in Taipei, Taiwan.
Medeon Biodesign, Inc. has the following listings and related stock indices.
Stock: TWSE: 6499 wb_incandescent